-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with imitation of Sitagliptin phosphate tablets submitted for production in Category 4, and it is expected to be mass-produced and deemed to have been reviewed
.
Sitagliptin is the world's first DPP-4 inhibitor, with global sales of 3.
306 billion U.
S.
dollars in 2020
.
.
Sitagliptin is the world's first DPP-4 inhibitor, with global sales of 3.
306 billion U.
S.
dollars in 2020
.
Sitagliptin is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Merck Neutrality, good cardiovascular safety and other advantages
.
In 2020, Merck’s Sitagliptin’s global sales were 3.
306 billion U.
S.
dollars
.
.
In 2020, Merck’s Sitagliptin’s global sales were 3.
306 billion U.
S.
dollars
.
Meinenet data shows that in recent years, the domestic market of Sitagliptin has been increasing.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
4 billion.
Yuan, a year-on-year increase of 45.
55%; 2021H1 sales exceeded 800 million yuan, a year-on-year increase of 32%
.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
4 billion.
Yuan, a year-on-year increase of 45.
55%; 2021H1 sales exceeded 800 million yuan, a year-on-year increase of 32%
.
The sales of sitagliptin terminal in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Among the six DPP-4 inhibitors that have been marketed in China, vildagliptin and saxagliptin have been included in the third and fifth batches of centralized procurement, while sitagliptin has not yet been included in the national centralized procurement
.
.
Currently, sitagliptin phosphate tablets have been produced and approved eight companies deemed too assessment, including CTTQ, East Sunshine Pharmaceutical, Zhejiang Pharmaceutical , Shijiazhuang Pharmaceutical Group, Yangtze River Pharmaceutical and so on
.
In addition, Qilu Pharmaceutical, Huahai Pharmaceutical, Lepu Pharmaceutical, Ganli Pharmaceutical.
.
.
9 companies ' applications for the listing of sitagliptin phosphate tablets are under review
.
.
In addition, Qilu Pharmaceutical, Huahai Pharmaceutical, Lepu Pharmaceutical, Ganli Pharmaceutical.
.
.
9 companies ' applications for the listing of sitagliptin phosphate tablets are under review
.
Kelun Pharmaceutical's registration status for sitagliptin phosphate tablets has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the company's first DPP-4 inhibitor
.
If it is successfully approved, it will be deemed to have been reviewed and become the company's first DPP-4 inhibitor
.
Data source: Mi Neiwang database
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with imitation of Sitagliptin phosphate tablets submitted for production in Category 4, and it is expected to be mass-produced and deemed to have been reviewed
.
Sitagliptin is the world's first DPP-4 inhibitor, with global sales of 3.
306 billion U.
S.
dollars in 2020
.
.
Sitagliptin is the world's first DPP-4 inhibitor, with global sales of 3.
306 billion U.
S.
dollars in 2020
.
Sitagliptin is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Merck Neutrality, good cardiovascular safety and other advantages
.
In 2020, Merck’s Sitagliptin’s global sales were 3.
306 billion U.
S.
dollars
.
.
In 2020, Merck’s Sitagliptin’s global sales were 3.
306 billion U.
S.
dollars
.
Meinenet data shows that in recent years, the domestic market of Sitagliptin has been increasing.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
4 billion.
Yuan, a year-on-year increase of 45.
55%; 2021H1 sales exceeded 800 million yuan, a year-on-year increase of 32%
.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
4 billion.
Yuan, a year-on-year increase of 45.
55%; 2021H1 sales exceeded 800 million yuan, a year-on-year increase of 32%
.
The sales of sitagliptin terminal in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Among the six DPP-4 inhibitors that have been marketed in China, vildagliptin and saxagliptin have been included in the third and fifth batches of centralized procurement, while sitagliptin has not yet been included in the national centralized procurement
.
.
Currently, sitagliptin phosphate tablets have been produced and approved eight companies deemed too assessment, including CTTQ, East Sunshine Pharmaceutical, Zhejiang Pharmaceutical , Shijiazhuang Pharmaceutical Group, Yangtze River Pharmaceutical and so on
.
In addition, Qilu Pharmaceutical, Huahai Pharmaceutical, Lepu Pharmaceutical, Ganli Pharmaceutical.
.
.
9 companies ' applications for the listing of sitagliptin phosphate tablets are under review
.
.
In addition, Qilu Pharmaceutical, Huahai Pharmaceutical, Lepu Pharmaceutical, Ganli Pharmaceutical.
.
.
9 companies ' applications for the listing of sitagliptin phosphate tablets are under review
.
Kelun Pharmaceutical's registration status for sitagliptin phosphate tablets has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the company's first DPP-4 inhibitor
.
If it is successfully approved, it will be deemed to have been reviewed and become the company's first DPP-4 inhibitor
.
Data source: Mi Neiwang database
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with imitation of Sitagliptin phosphate tablets submitted for production in Category 4, and it is expected to be mass-produced and deemed to have been reviewed
.
Sitagliptin is the world's first DPP-4 inhibitor, with global sales of 3.
306 billion U.
S.
dollars in 2020
.
.
Sitagliptin is the world's first DPP-4 inhibitor, with global sales of 3.
306 billion U.
S.
dollars in 2020
.
Sitagliptin is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Merck Neutrality, good cardiovascular safety and other advantages
.
In 2020, Merck’s Sitagliptin’s global sales were 3.
306 billion U.
S.
dollars
.
.
In 2020, Merck’s Sitagliptin’s global sales were 3.
306 billion U.
S.
dollars
.
Meinenet data shows that in recent years, the domestic market of Sitagliptin has been increasing.
In 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
4 billion.
Yuan, a year-on-year increase of 45.
55%; 2021H1 sales exceeded 800 million yuan, a year-on-year increase of 32%
.
Hospital hospital hospitalIn 2020, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
4 billion.
Yuan, a year-on-year increase of 45.
55%; 2021H1 sales exceeded 800 million yuan, a year-on-year increase of 32%
.
The sales of sitagliptin terminal in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Among the six DPP-4 inhibitors that have been marketed in China, vildagliptin and saxagliptin have been included in the third and fifth batches of centralized procurement, while sitagliptin has not yet been included in the national centralized procurement
.
.
Currently, sitagliptin phosphate tablets have been produced and approved eight companies deemed too assessment, including CTTQ, East Sunshine Pharmaceutical, Zhejiang Pharmaceutical , Shijiazhuang Pharmaceutical Group, Yangtze River Pharmaceutical and so on
.
In addition, Qilu Pharmaceutical, Huahai Pharmaceutical, Lepu Pharmaceutical, Ganli Pharmaceutical.
.
.
9 companies ' applications for the listing of sitagliptin phosphate tablets are under review
.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise Enterprise.
In addition, Qilu Pharmaceutical, Huahai Pharmaceutical, Lepu Pharmaceutical, Ganli Pharmaceutical.
.
.
9 companies ' applications for the listing of sitagliptin phosphate tablets are under review
.
Kelun Pharmaceutical's registration status for sitagliptin phosphate tablets has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the company's first DPP-4 inhibitor
.
If it is successfully approved, it will be deemed to have been reviewed and become the company's first DPP-4 inhibitor
.
Data source: Mi Neiwang database
